泓博医药 (301230)
PharmaResources (Shanghai) Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.
Listing Date2022-11-01
Issue Price40RMB
Registered Capital13958.660510k RMB
Legal RepresentativePing Chen
Registered AddressBuilding 23, No. 315 Qingda Road, Pudong New District, Shanghai
IndustryMedical Services
Main BusinessA one-stop integrated service provider for new drug R&D and commercial production, dedicated to drug discovery, research and development of pharmaceutical processes, and commercial production of APIs and intermediates.
Company ProfileShanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. is a one-stop integrated service provider for new drug R&D and commercial production, dedicated to drug discovery, research and development of pharmaceutical processes, and commercial production of APIs and intermediates. The company focuses on key segments of the new drug R&D industry chain, building a comprehensive technology service platform covering drug discovery, process research and development, as well as a commercial production platform for the manufacturing of key new drug intermediates and proprietary products.
The company is one of China's early CRO companies providing preclinical drug R&D services to international clients, with over 10 years of experience in small molecule drug R&D services and production. It has successively assisted multiple overseas biopharmaceutical companies in successfully developing 17 clinical candidate drugs, of which 2 have been approved for marketing, 2 are in Phase III clinical trials, 2 are in Phase II clinical trials, 4 are in Phase I clinical trials, 2 are in the clinical application stage, and 5 are in the preclinical stage. Additionally, the company has provided nearly 100 innovative drug process research and development projects for domestic and international clients. The company currently holds 23 authorized invention patents, with rich accumulation of patents and technology, widely recognized by overseas innovative drug R&D clients, and engages in in-depth cooperation with them.
Stock Details
1. Key Indicators
- Total Shares(W): 13958.66
- Circulating A-Shares(W): 12561.58
- Earnings Per Share(RMB): 0.2489
- Net Assets Per Share(RMB): 7.3516
- Operating Revenue(W RMB): 51440.12
- Total Profit(W RMB): 3182.52
- Net Profit Attributable to Parent(W RMB): 3474.96
- Net Profit Growth Rate(%): 127.96
- Weighted Return on Equity(%): 3.30
- Operating Cash Flow Per Share(RMB): 0.5910
- Undistributed Profit Per Share(RMB): 0.9946
- Capital Reserve Per Share(RMB): 5.5236
2. Main Business
The main business covers:
- Drug Discovery
- Research and Development of Pharmaceutical Processes
- Commercial Production of API Intermediates
3. Company Basic Information
- Company Name: PharmaResources (Shanghai) Co., Ltd.
- Listing Date: 2022-11-01
- Industry: Research and Experimental Development
- Address: Building 23, No. 315 Qingda Road, Pudong New Area, Shanghai, China
- Website: www.pharmaresources.cn
- Company Profile: The company's predecessor, Shanghai Hongbo Zhiyuan Pharmaceutical Technology Co., Ltd., was restructured into a joint-stock company in November 2015. It is a foreign-invested joint-stock company registered in the Pudong New Area of Shanghai, primarily engaged in the research, development, and transfer of proprietary technologies for new drugs and related biotechnology, as well as providing related technical services and consulting.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenyang Fubang Investment Co., Ltd. | General Legal Person | 729.32 | 9.49 |
| 2 | Shenzhen Yingyuntong No.2 Investment Partnership (Limited Partnership) | General Legal Person | 400.00 | 5.20 |
| 3 | Beijing Zhongfu Growth Equity Investment Center (Limited Partnership) | General Legal Person | 280.28 | 3.65 |
| 4 | Huatai Asset-ICBC-Huatai Zengxin Investment Product | Asset Management Plan | 185.12 | 2.41 |
| 5 | Great Wall Consumption Growth Hybrid Securities Investment Fund Class A | Fund | 160.09 | 2.08 |
| 6 | Dingtai Haifu Investment Management Co., Ltd. | General Legal Person | 140.54 | 1.83 |
| 7 | Galaxy Kangle Stock Securities Investment Fund Class A | Fund | 44.15 | 0.57 |
| 8 | Penghua CSI 1000 Index Enhanced Securities Investment Fund Class A | Fund | 25.42 | 0.33 |
5. Concept Sectors
- Smart Healthcare
- Artificial Intelligence
- CXO Concept
- Innovative Drugs
- ChatGPT
- Multimodal AI
- Synthetic Biology
- AI in Healthcare
- Margin Trading & Securities Lending
- Shareholder Reduction
- Overseas Business
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information